Tetraphase Plummets After Antibiotic Fails Late-Stage Trial

  • Shares of drug developer fall 80 percent in late trading
  • Drug failed to beat generic medicine in 908-person trial

Tetraphase Pharmaceuticals Inc. fell 80 percent in late trading Tuesday after a study found that its experimental antibiotic wasn’t better than a standard generic treatment.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.